Resolve mdx
for Urinary Tract Infection

SAMPLE
Patient Report

Patient

Patient Name: Jon Doe
Date of Birth: 02-22-1952
MRN/Patient #: 1234-1

Specimen

Specimen #: 123-456-789
Collection Date: 03-10-2023
Received Date: 03-11-2023
Report Date: 03-13-2023
Specimen Type: Clean catch urine
Mdxhealth Accession #: A00000

Account

Physician: Dr. Smith
Account: Urology Care
Address: 12345 Alton
City, State, Zip: Irvine, CA 92618

PATIENT RESULT: PATHOGEN(S) DETECTED

Pathogen(s) Detected

Pathogen(s) Detected	CFU/ml
Escherichia coli	4.56×10^5
Enterococcus faecalis	2.37×10^3

Resistance Gene(s) Detected

Resistance Gene(s) Detected	Antimicrobial Resistance
Vancomycin Resistance Gene (VRE)	Vancomycin

Patient Susceptible Antimicrobials

- Amoxicillin-clavulanate PO
- Fosfomycin PO
- Ampicillin PO/IM/IV
- Ciprofloxacin PO/IV
- Doxycycline PO/IV
- Levofloxacin PO/IV
- Minocycline PO/IV

Patient Susceptibility Report

Report Key
S = Susceptible I = Intermediate R = Resistant
SDD = Susceptible-Dose Dependent *R = Data not patient specific
N/A = Detected organism has variable results SNP = Susceptibility not performed

Antimicrobial	Formulation	Antimicrobial Phenotypic Susceptibility	Supportive Data from Sanford Guide	
			Escherichia coli	Enterococcus faecalis
Amoxicillin-clavulanate	PO	S	✓	✓
Fosfomycin	PO	S	✓	✓
Ampicillin	PO/IM/IV	S	✓	✓
Ciprofloxacin	PO/IV	S	✓	
Doxycycline	PO/IV	S	✓	✓
Levofloxacin	PO/IV	S	✓	
Minocycline	PO/IV	S	✓	✓
Nitrofurantoin	PO	I	✓	✓
Linezolid	PO	I		✓
Tetracycline	PO/IV	I	✓	✓
Cefaclor	PO	R	✓	
Cefdinir	PO	R	✓	
Cephalexin	PO	R	✓	

Antimicrobial	Formulation	Antimicrobial Phenotypic Susceptibility	Supportive Data from Sanford Guide	
			Escherichia coli	Enterococcus faecalis
Ofloxacin	PO/IM/IV	R	✓	
Trimethoprim-sulfamethozazole	PO/IV	R	✓	
Cefazolin	IM/IV	R	✓	
Cefepime	IM/IV	R	✓	
Cefoxitin	IM/IV	R	✓	
Ceftriaxone	IM/IV	R	✓	
Gentamicin	IM/IV	R	✓	✓
Ampicillin-sulbactam	IV	R	✓	✓
Aztreonam	IV	R	✓	
Meropenem	IV	R	✓	
Piperacillin-tazobactam	IV	R	✓	✓
Vancomycin	PO/IV	R		

COMMENT:

RESISTANCE GENE(S) - NOT DETECTED:

Extended Spectrum Beta Lactamase, Methicillin, Fluoroquinolone, Carbapenem, Trimethoprim

PATHOGEN(S) - NOT DETECTED:

BACTERIA:

- Acinetobacter baumannii
- Citrobacter freundii
- Citrobacter koseri
- Enterobacter cloacae
- Enterococcus faecium
- Klebsiella aerogenes
- Klebsiella oxytoca
- Klebsiella pneumoniae
- Morganella morganii
- Proteus mirabilis
- Pseudomonas aeruginosa
- Serratia marcescens
- Staphylococcus aureus
- Staphylococcus epidermidis
- Staphylococcus saprophyticus
- Streptococcus pyogenes

YEAST:

- Candida albicans

Information About the Patient Susceptibility Report:

Gray checkmarks indicate there is supportive evidence from the Sanford Guide that the antibiotic, either FDA approved or off label, can be used for treatment. The Sanford Guide (https://webedition.sanfordguide.com/en) provides treatment guidelines for infection by bacterial pathogens only. Treatment options are not intended to be prescriptive for any specific patient. Appropriate medical judgment should be exercised by the attending physician before prescribing a course of treatment.

Methodology and Clinical Significance:

Pathogens and Resistance Genes are detected through real time multiplex PCR. Pathogens are quantified based on cells per milliliter of urine based on the following limit of detection: Candida albicans (1×10^3) Acinetobacter baumannii (1×10^3), Citrobacter freundii (1×10^3), Citrobacter koseri ($1x\ 10^3$), Enterobacter cloacae (1×10^3), Enterococcus faecalis (1×10^3), Enterococcus faecium ($1x\ 10^4$), Escherichia coli (1×10^3), Klebsiella aerogenes (1×10^3), Klebsiella oxytoca (1×10^3), Klebsiella pneumoniae (1×10^3), Morganella morganii (1×10^3), Proteus mirabilis (1×10^3), Pseudomonas aeruginosa (1×10^3), Serratia marcescens (1×10^3), Staphylococcus aureus (1×10^4), Staphylococcus epidermidis (1×10^3), Staphylococcus saprophyticus (1×10^3), Streptococcus pyogenes (1×10^3). Resistance genes are reported as “detected” or “not detected.” Antimicrobial susceptibility is determined by testing the whole urine polymicrobial population against a panel of antimicrobial agents.

Disclaimer:

Mdxhealth is regulated under the Clinical Laboratory Improvement Amendments (CLIA) as an accredited laboratory to perform high complexity clinical testing. The Resolve mdx test was developed, and its performance characteristics determined by mdxhealth. It has not been cleared or approved by the US Food and Drug Administration. The FDA has determined such clearance or approval is not necessary. Use outside of this indication has not been validated by mdxhealth. Test results should be interpreted in conjunction with other laboratory and clinical data available to the clinician and relevant guidelines on the decision for Urinary Tract Infection.

This test was performed by Delta Laboratories LLC dba mdxhealth Central, 7000 Preston Road, Suite 1500, Plano, TX 75024.
CLIA# 45D2229819

Joseph L. Sailors, M.D.

Joseph L. Sailors, MD, Laboratory Director